Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Decrease in Short Interest

Lyell Immunopharma, Inc. (NASDAQ:LYEL) was the target of a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 10,660,000 shares, a decline of 19.4% from the September 15th total of 13,220,000 shares. Based on an average trading volume of 667,100 shares, the short-interest ratio is presently 16.0 days. Approximately 9.4% of the shares of the company are short sold.

Hedge Funds Weigh In On Lyell Immunopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Opaleye Management Inc. bought a new stake in shares of Lyell Immunopharma during the 1st quarter worth $7,482,000. Caxton Associates LP boosted its holdings in shares of Lyell Immunopharma by 359.1% in the 1st quarter. Caxton Associates LP now owns 174,657 shares of the company’s stock worth $389,000 after purchasing an additional 136,611 shares in the last quarter. Invenomic Capital Management LP raised its holdings in shares of Lyell Immunopharma by 16.8% during the 1st quarter. Invenomic Capital Management LP now owns 871,525 shares of the company’s stock valued at $1,944,000 after buying an additional 125,110 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Lyell Immunopharma by 1.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,731,477 shares of the company’s stock worth $15,013,000 after buying an additional 92,594 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Lyell Immunopharma during the first quarter worth approximately $191,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Stock Performance

Lyell Immunopharma stock traded down $0.02 during midday trading on Tuesday, reaching $1.17. 315,118 shares of the stock were exchanged, compared to its average volume of 895,586. The company’s fifty day moving average is $1.33 and its 200-day moving average is $1.86. Lyell Immunopharma has a 52 week low of $1.06 and a 52 week high of $3.26. The firm has a market cap of $298.28 million, a PE ratio of -1.30 and a beta of -0.53.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, August 7th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.02. Lyell Immunopharma had a negative return on equity of 33.35% and a negative net margin of 389,368.50%. The business had revenue of $0.01 million during the quarter. On average, sell-side analysts anticipate that Lyell Immunopharma will post -0.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Bank of America reduced their target price on shares of Lyell Immunopharma from $9.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, June 27th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a report on Monday, August 19th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.